Navigation Links
Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
Date:11/21/2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Piper Jaffray 24th Annual Healthcare Conference on Wednesday, November 28, 2012, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) at The New York Palace Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, and Craig M. Audet, Arena's Senior Vice President, Operations and Head of Global Regulatory Affairs, are scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

Arena also announced today that it is scheduled to present at the Leerink Swann 6th Annual POLARxPRESS Bus Tour on November 28, 2012, in New York City. This presentation will not be webcast.

About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, was approved by the US Food and Drug Administration in June 2012, and is under review for regulatory approval in additional jurisdictions. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information about Arena, please visit www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the regulatory review of BELVIQ; and Arena's focus, goals, strategy, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from BELVIQ, including the impact of competition; the timing and outcome of regulatory review is uncertain; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersCindy McGee, Vice President,

David Schull, PresidentInvestor Relations & Alliance Management  

david.schull@russopartnersllc.comcmcgee@arenapharm.com  

858.717.2310858.453.7200, ext. 1479www.arenapharm.com
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
3. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
4. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
5. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
8. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
9. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
10. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
11. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Global Pulmonary Drugs Market: Snapshot ... current as well as future prospects of the ... companies and intermediaries engaged in the manufacture and ... as well as new entrants planning to enter ... summary along with a market snapshot providing overall ...
(Date:12/7/2016)... , Dec. 7, 2016  The Corporate ... healthcare manager to call them anytime at 866-714-6466 if ... managers to sell more drugs. Aside from the innocent ... taxpayers as well, because often-times these practices target Medicare recipients ... http://photos.prnewswire.com/prnh/20161206/446240 ...
(Date:12/7/2016)... , Dec. 7, 2016 According to responses ... more than one-third (38%) of patients with non-small cell lung ... growth factor receptor (EGFR) genetic mutation status. The findings of ... LBA ID #6067 #P3.02b ) at the 2016 ... Austria . The survey results revealed an ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed ... a researcher at the Icahn School of Medicine at Mount Sinai has found. ... that when young children are exposed to secondhand marijuana smoke, measurable amounts of ...
(Date:12/7/2016)... ... 2016 , ... In the early morning of October 30, Newton County Sheriff’s ... he lost control of his patrol car. The vehicle overturned into an embankment, causing ... to Atlanta Medical Center, where he later succumbed to his injuries. Justin White leaves ...
(Date:12/7/2016)... ... December 07, 2016 , ... They are musicians and ... and wives, brothers and fathers, from New England and around the nation. What do ... and are brought together in a beautiful and compelling new photographic exhibit debuting Friday, ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... insurance and financial planning services to families and business owners in the greater ... on behalf of the Dallas Fallen Officer Foundation. , Established in 2009 by ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated radio ... on Voice of America, declared on her radio program in November 2016 the need ... when these bullies attack leaders in corporate America, they are trying to take advantage ...
Breaking Medicine News(10 mins):